EKSO BIONICS HOLDINGS, INC.

ChronoScale Corporation secured an unsecured Demand Grid Promissory Note with Applied Digital Corporation, providing a line of credit up to $100 million for working capital and general corporate purposes. The note bears interest at the short-term Applicable Federal Rate, compounded semiannually, and allows for prepayment without penalty. No advances have been made under the note to date. This transaction involves related parties, as Applied Digital Corporation and its subsidiary collectively own approximately 96% of ChronoScale's common stock, and several individuals serve on both companies' boards.

ChronoScale Corporation, the parent company of Ekso Bionics, Inc., has announced a plan to divest its wholly owned subsidiary, Ekso Bionics, Inc. This strategic move aims to allow ChronoScale to focus its operations solely on its cloud business. The divestiture is expected to be completed during the first fiscal quarter, and ChronoScale anticipates incurring material charges, including severance and lease termination costs, though specific estimates are not yet available.

Ekso Bionics announced that Phantom Performance-Based Restricted Stock Unit (PSU) Awards granted to executives Mr. Davis, Mr. Wong, and Mr. Jones on November 5, 2025, have vested. This vesting was triggered by the achievement of a Stock Price Goal and the occurrence of a Change in Control on May 5, 2026. The Board also amended the settlement terms, changing them from cash-only to a combination of common stock and cash for Mr. Davis, and exclusively common stock for Mr. Wong and Mr. Jones.

ChronoScale Corporation announced the appointment of Cenly Chen as its new Chief Executive Officer and a member of its Board of Directors. Ms. Chen brings over two decades of experience in scaling enterprise infrastructure and high-performance computing platforms, most recently serving as Chief Growth Officer at Super Micro Computer, Inc. The appointment comes as ChronoScale, formed from Applied Digital's cloud business and EKSO Bionics, aims to expand capacity and meet accelerating demand for AI compute infrastructure.

Ekso Bionics Holdings, Inc. has completed its previously announced business combination, rebranding as ChronoScale Corporation. As part of the transaction, Applied Digital Cloud Corporation became a wholly-owned subsidiary of ChronoScale. Applied Digital Corporation and its subsidiary now collectively hold approximately 97% of ChronoScale's outstanding common stock, following a $15.75 million PIPE investment and a share exchange. The company's common stock has commenced trading on The Nasdaq Capital Market under the new ticker symbol "CHRN".

Ekso Bionics Holdings, Inc. announced the consummation of its previously disclosed business combination transaction, effective May 5, 2026. In connection with this, the company will change its name to ChronoScale Corporation and its Nasdaq ticker symbol to "CHRN". Additionally, Ekso Bionics entered into a PIPE investment with Applied Digital Corporation, selling 1,311,407 shares for approximately $15.75 million.

Ekso Bionics Holdings, Inc. reported a significant decline in revenue and a widened net loss for the first quarter ended March 31, 2026. Revenue decreased by 36.5% year-over-year to $2.14 million, while the net loss increased to $(6.89) million from $(2.89) million in the prior year. The company also disclosed substantial doubt about its ability to continue as a going concern, with current cash expected to fund operations only into early Q3 2026, despite raising $5.27 million from preferred stock and warrant issuance.

Ekso Bionics Holdings, Inc. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment provides updated administrative details regarding the company's regulatory status. The filing indicates that Ekso Bionics is a non-accelerated filer and a smaller reporting company, with the aggregate market value of its common stock held by non-affiliates recorded at $8,158,292 as of June 30, 2025.